English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective  To evaluate the efficacy and safety of  Lactobacillus reuteri  DSM 17938 for treating infantile colic.    Methods  A systematic literature retrieval was carried out to obtain randomized controlled trials of  L .  reuteri  DSM 17938 for infantile colic. Trials were performed before May 2015 and retrieved from the PubMed, EMBASE, Cochrane library, CNKI, WanFang, VIP, and CBM databases. Data extraction and quality evaluation of the trials were performed independently by two investigators. A meta-analysis was performed using STATA version 12.0.    Results  Six randomized controlled trials of 423 infants with colic were included. Of these subjects, 213 were in the  L .  reuteri  group, and 210 were in the placebo group.  Lactobacillus reuteri  increased colic treatment effectiveness at two weeks (RR = 2.84; 95% CI: 1.24–6.50;  p  = 0.014) and three weeks (relative risk [RR] = 2.33; 95% CI: 1.38–3.93;  P  = 0.002) but not at four weeks (RR = 1.41; 95% CI: 0.52–3.82;  P  = 0.498).  Lactobacillus reuteri  decreased crying time (min/d) at two weeks (weighted mean difference [WMD] = –42.89; 95% CI: –60.50 to –25.29;  P  = 0.000) and three weeks (WMD = –45.83; 95% CI: –59.45 to –32.21;  P  = 0.000). In addition,  L .  reuteri  did not influence infants’ weight, length or head circumference and was not associated with serious adverse events.    Conclusions    Lactobacillus reuteri  possibly increased the effectiveness of treatment for infantile colic and decreased crying time at two to three weeks without causing adverse events. However, these protective roles are usurped by gradual physiological improvements. The study is limited by the heterogeneity of the trials and should be considered with caution. Higher quality, multicenter randomized controlled trials with larger samples are needed.

plos one

The Efficacy and Safety of the Probiotic Bacterium Lactobacillus reuteri DSM 17938 for Infantile Colic: A Meta-Analysis of Randomized Controlled Trials